Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Bristol-Myers Squibb

Founders John Ripley Myers William McLaren Bristol

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 47
Average round size
info
The average size of a deal this fund participated in
$55M
Portfolio companies 39
Rounds per year 0.35
Lead investments 8
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.17
Exits 7
Key employees 1

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

Bristol-Myers Squibb is the famous Corporate Investor, which was founded in 1887. The fund was located in North America if to be more exact in United States. The main department of described Corporate Investor is located in the New York.

The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 3 or 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Health Diagnostics, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Blade Therapeutics, PathAI, Personal Genome Diagnostics (PGD). Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Bristol-Myers Squibb, startups are often financed by Sprout Group, SR One, Refactor Capital. The meaningful sponsors for the fund in investment in the same round are Seventure Partners, Ysios Capital, Yonghua Capital. In the next rounds fund is usually obtained by Partners Investment, Symbiosis Group, Symbiosis.

The top amount of exits for fund were in 2014. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. This Bristol-Myers Squibb works on 2 percentage points more the average amount of lead investments comparing to the other organizations. The fund is generally included in less than 2 deals every year. The common things for fund are deals in the range of 10 - 50 millions dollars. Considering the real fund results, this Corporate Investor is 34 percentage points more often commits exit comparing to other organizations.

The fund was created by John Ripley Myers, William McLaren Bristol.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Bristol-Myers Squibb:
Typical Co-investors
Bristol-Myers Squibb is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Bristol-Myers Squibb:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Cajal Neuroscience

Biotechnology
Pharmaceutical
$96M29 Nov 2022 Seattle, Washington, United States

Kura Oncology

Biopharma
Biotechnology
Genetics
Health Care
Medical
$25M03 Nov 2022 San Diego, California, United States

SyntheX

Biotechnology
Life Science
Pharmaceutical
Therapeutics
04 Oct 2022 San Francisco, California, United States

Capstan Therapeutics

Biotechnology
Health Care
Therapeutics
$102M14 Sep 2022 San Diego, California, United States

Autobahn Therapeutics

Biotechnology
Health Care
Life Science
Therapeutics
$32M08 Sep 2022 San Diego, California, United States

BigHat Biosciences

Artificial Intelligence
Biotechnology
Medical
Therapeutics
$75M20 Jul 2022 California, United States

Owkin

Artificial Intelligence
Biotechnology
Clinical Trials
Machine Learning
Other Healthcare Technology Systems
Software
$50M08 Jun 2022 New York, New York, United States

Transition Bio

Health Care
Health Diagnostics
Medical
$50M02 Jun 2022 Cambridge, Massachusetts, United States

Sapience Therapeutics

Biotechnology
Medical
Therapeutics
$41M31 May 2022 New York, United States
News
TreeFrog Therapeutics Raises $75M In Series B Financing

– TreeFrog Therapeutics, a Bordeaux, France-based biotech startup focused on developing stem cell-derived cell therapies for millions of patients, closed a $75m (€64M) Series B financing round, bringing the total funding to date to $83m (€70m).
– The round was led by Bpifrance Large Venture, part of the French Public Investment Bank, joined by U.S. investment firm Leonard Green & Partners L.P., global pharmaceutical company Bristol Myers Squibb, and European venture capital team XAnge.
– The company intends to use the funds to deploy biomimetic C-StemTM technology for clinical-grade manufacturing, grow and advance to the clinic a comprehensive pipeline of cell therapies, and finance the opening of technological hubs in Boston, MA, and Kobe, Japan.

Obsidian Therapeutics Closes $115M Series B Financing

– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Bristol-Myers Squibb?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: